Reaktionsgleichung
[Br:1][C:2]1[CH:3]=[CH:4][C:5]2[N:6]([C:8]([C:18](=O)[C:19]#[CH:20])=[C:9]([C:11]3[CH:16]=[CH:15][C:14]([F:17])=[CH:13][CH:12]=3)[N:10]=2)[CH:7]=1.Cl.[CH:23]1([NH:28][C:29]([NH2:31])=[NH:30])[CH2:27][CH2:26][CH2:25][CH2:24]1.C(=O)([O-])[O-]>>[Br:1][C:2]1[CH:3]=[CH:4][C:5]2[N:6]([C:8]([C:18]3[CH:19]=[CH:20][N:31]=[C:29]([NH:28][CH:23]4[CH2:27][CH2:26][CH2:25][CH2:24]4)[N:30]=3)=[C:9]([C:11]3[CH:16]=[CH:15][C:14]([F:17])=[CH:13][CH:12]=3)[N:10]=2)[CH:7]=1Komponenten
4
Versuchsvorschrift
In a similar manner as described in Example 2 from 1-[6-bromo-2-(4-fluorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-propyn-1-one (1.0 g, 2.9 mmol), cyclopentylguanidine hydrochloride (0.71 g, 4.4 mmol) and anhydrous carbonate (0.6 g, 4.4 mmol), was obtained N-{4-[6-bromo-2-(4-fluorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl}-N-cyclopentylamine (0.8 g, 61%) as a solid. 1H NMR (CDCl3) δ 10.0 (broad s, 1H), 8.13 (d, 1H), 7.65 (m, 3H), 7.44 (dd, 1H), 7.17 (t, 2H), 6.45 (s, 1H), 5.30 (d, 1H), 4.40 (m, 1H), 2.1 (m, 2H), 1.4–2.0 (m, 6H); 19F NMR (CDCl3) δ −112.8; MS m/z 452 (M+1).
Quellen und Nachweise
- ORD-Eintrag
- ord-09122457c5c54ed2a8723ccbee82855c
- Quelldatensatz
- uspto-grants-2007_03
- Patentnummer
- US07186714B2
Verknüpfte Notizen
Wird geladen…